KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Bionano Genomics (BNGO) Net Margin (2017 - 2025)

Bionano Genomics (BNGO) has disclosed Net Margin for 9 consecutive years, with 99.77% as the latest value for Q4 2025.

  • Quarterly Net Margin rose 15213.0% to 99.77% in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 92.59% through Dec 2025, up 27281.0% year-over-year, with the annual reading at 92.59% for FY2025, 27281.0% up from the prior year.
  • Net Margin hit 99.77% in Q4 2025 for Bionano Genomics, up from 115.42% in the prior quarter.
  • In the past five years, Net Margin ranged from a high of 48.04% in Q1 2025 to a low of 1208.05% in Q3 2023.
  • Historically, Net Margin has averaged 400.52% across 5 years, with a median of 424.95% in 2023.
  • Biggest five-year swings in Net Margin: plummeted -76754bps in 2023 and later soared 61315bps in 2025.
  • Year by year, Net Margin stood at 364.15% in 2021, then decreased by -29bps to 470.81% in 2022, then increased by 13bps to 409.39% in 2023, then skyrocketed by 38bps to 251.9% in 2024, then surged by 60bps to 99.77% in 2025.
  • Business Quant data shows Net Margin for BNGO at 99.77% in Q4 2025, 115.42% in Q3 2025, and 101.84% in Q2 2025.